Patents by Inventor Jennifer D. Venable

Jennifer D. Venable has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of KEAP1-Nrf2 protein-protein interaction
    Patent number: 11897900
    Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: February 13, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
  • Imidazopyrrolopyridine as inhibitors of the JAK family of kinases
    Patent number: 11827638
    Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: November 28, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Genesis M. Bacani, Wenying Chai, Tatiana Koudriakova, Paul J. Krawczuk, Kevin D. Kreutter, Kristi Leonard, Michele C. Rizzolio, Mark Seierstad, Russell C. Smith, Mark S. Tichenor, Jennifer D. Venable, Aihua Wang
  • IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS
    Publication number: 20230147458
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: September 26, 2022
    Publication date: May 11, 2023
    Inventors: Steven D. Goldberg, Douglas C. Behenna, Deane Gordon, Luke E. Hanna, Steven A. Loskot, Stefan McCarver, Steven P. Meduna, Brock T. Shireman, Alexander E. Valdes, Jennifer D. Venable, Dongpei Wu, Xiaohua Xue
  • INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE
    Publication number: 20230097422
    Abstract: The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
    Type: Application
    Filed: March 25, 2022
    Publication date: March 30, 2023
    Inventors: Nidhi ARORA, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Kevin D. Kreutter, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J.M. Wiener
  • INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE
    Publication number: 20230013755
    Abstract: The present disclosure is directed to the use of a compound of Formula (III) in the treatment of malignancies.
    Type: Application
    Filed: June 2, 2022
    Publication date: January 19, 2023
    Inventors: Sriram BALASUBRAMANIAN, Ivo CORNELISSEN, Yue GUO, Jocelyn H. LEU, Kathryn E. PACKMAN, James Alexander PALMER, Ulrike PHILIPPAR, Navin RAO, Mark S. TICHENOR, Jennifer D. VENABLE, John J. M. WIENER, Xin MIAO
  • INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION
    Publication number: 20220315604
    Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
    Type: Application
    Filed: December 18, 2020
    Publication date: October 6, 2022
    Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
  • Inhibitors of KEAP1-Nrf2 protein-protein interaction
    Patent number: 11427601
    Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: August 30, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
  • Inhibitors of Bruton's tyrosine kinase and methods of their use
    Patent number: 11319329
    Abstract: The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: May 3, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Kevin D. Kreutter, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J. M. Wiener
  • IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES
    Publication number: 20210206768
    Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.
    Type: Application
    Filed: March 16, 2021
    Publication date: July 8, 2021
    Inventors: Genesis M. Bacani, Wenying Chai, Tatiana Koudriakova, Paul J. Krawczuk, Kevin D. Kreutter, Kristi Leonard, Michele C. Rizzolio, Mark Seierstad, Russell C. Smith, Mark S. Tichenor, Jennifer D. Venable, Aihua Wang
  • Imidazopyrrolopyridine as inhibitors of the JAK family of kinases
    Patent number: 10981911
    Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: April 20, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Genesis M. Bacani, Wenying Chai, Tatiana Koudriakova, Paul J. Krawczuk, Kevin D. Kreutter, Kristi Leonard, Michele C. Rizzolio, Mark Seierstad, Russell C. Smith, Mark S. Tichenor, Jennifer D. Venable, Aihua Wang
  • INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE
    Publication number: 20210101910
    Abstract: The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
    Type: Application
    Filed: May 13, 2020
    Publication date: April 8, 2021
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Kevin D. Kreutter, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J.M. Wiener
  • Inhibitors of KEAP1-Nrf2 protein-protein interaction
    Patent number: 10947252
    Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: March 16, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
  • Inhibitors of Bruton's tyrosine kinase and method of their use
    Patent number: 10934310
    Abstract: The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: March 2, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Min Cai, Wei Chen, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Kevin D. Kreutter, Gang Li, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J. M. Wiener, Yao Wu, Kun Xiao, Feihuang Zhang, Yaoping Zhu
  • Inhibitors of Bruton's tyrosine kinase and methods of their use
    Patent number: 10822348
    Abstract: The present disclosure is directed to compounds of formula I? and methods of their use and preparation, as well as compositions comprising compounds of formula I?.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: November 3, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Min Cai, Wei Chen, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Baoyu Hao, Kevin D. Kreutter, Gang Li, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J. M. Wiener, Yao Wu, Yaoping Zhu, Feihuang Zhang, Zheng Zhang, Kun Xiao
  • Inhibitors of Bruton's tyrosine kinase and method of their use
    Patent number: 10800792
    Abstract: The present disclosure is directed to compounds of formula I? and methods of their use and preparation, as well as compositions comprising compounds of formula I?.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: October 13, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Min Cai, Wei Chen, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Baoyu Hao, Kevin D. Kreutter, Gang Li, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J. M. Wiener, Yao Wu, Yaoping Zhu, Feihuang Zhang, Zheng Zhang, Kun Xiao
  • Inhibitors of Bruton's tyrosine kinase and method of their use
    Patent number: 10717745
    Abstract: The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: July 21, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Min Cai, Wei Chen, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Kevin D. Kreutter, Gang Li, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J. M. Wiener, Yao Wu, Kun Xiao, Feihuang Zhang, Yaoping Zhu
  • Inhibitors of Bruton's tyrosine kinase and methods of their use
    Patent number: 10689396
    Abstract: The present disclosure is directed to compounds of formula I? and methods of their use and preparation, as well as compositions comprising compounds of formula I?.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: June 23, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Min Cai, Wei Chen, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Baoyu Hao, Kevin D. Kreutter, Gang Li, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J. M. Wiener, Yao Wu, Yaoping Zhu, Feihuang Zhang, Zheng Zhang, Kun Xiao
  • INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION
    Publication number: 20200055874
    Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
    Type: Application
    Filed: August 19, 2019
    Publication date: February 20, 2020
    Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
  • IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES
    Publication number: 20190322665
    Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.
    Type: Application
    Filed: December 15, 2017
    Publication date: October 24, 2019
    Inventors: Genesis M. Bacani, Wenying Chai, Tatiana Koudriakova, Paul J. Krawczuk, Kevin D. Kreutter, Kristi Leonard, Michele C. Rizzolio, Mark Seierstad, Russell C. Smith, Mark S. Tichenor, Jennifer D. Venable, Aihua Wang
  • INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE
    Publication number: 20190284204
    Abstract: The present disclosure is directed to compounds of formula I? and methods of their use and preparation, as well as compositions comprising compounds of formula I?.
    Type: Application
    Filed: May 15, 2019
    Publication date: September 19, 2019
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Min Cai, Wei Chen, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Baoyu Hao, Kevin D. Kreutter, Gang Li, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J.M. Wiener, Yao Wu, Yaoping Zhu, Feihuang Zhang, Zheng Zhang, Kun Xiao